Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Inhaled TD-0903 for Acute Lung Injury Associated with COVID-19
2020-001807-18Phase 2Unknown
- Sponsor
- Theravance Biopharma, Inc.
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute lung injury (ALI) and Viral lower respiratory tract infection (VLRTI) comparing TD-0903 inhalation with Placebo inhalation (2 arms). Primary endpoints: Primary endpoint Part 1 and Endpoints Part 2. Status: unknown.
02
Drugs
nezulcitinib
03
Conditions
acute lung injury (ALI)Viral lower respiratory tract infection (VLRTI)
Beyond the preview
Go deeper on 2020-001807-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001807-18.